Clinical trials: Secondary Hyperparathyroidism
Secondary Hyperparathyroidism, Chronic Kidney Disease
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.
- Trial name
- NCT02341417
- Testing
- Cinacalcet
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 28 people
- Sponsor
- Amgen
Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism
Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia…
- Trial name
- Cin-ca (NCT07007338)
- Testing
- Supplementary blood samples and urines samples
- Where
- 7 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
CKD Stage 3, CKD Stage 4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D…
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Trial name
- NCT07494045
- Testing
- CTAP101
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Disease, Secondary Hyperparathyroidism
Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
The primary objective was to evaluate the efficacy of cinacalcet for reducing the plasma intact parathyroid hormone (iPTH) level by ≥ 30%.
- Trial name
- NCT02138838
- Testing
- Cinacalcet HCl, Standard of Care
- Where
- 60 sites in United States, Belgium and 14 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Sodium Zirconium Cyclosilicate, Hyperkalemia
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
Sodium zirconium cyclosilicate (SZC) has been demonstrated for its serum potassium-lowering efficacy and safety in hyperkalemia hemodialysis patients. However, the effects of SZC during the perioperative period remained unknown.
- Conditions
- Sodium Zirconium Cyclosilicate, Hyperkalemia, Hyperparathyroidism, Secondary
- Trial name
- SZC (NCT05382988)
- Testing
- Sodium zirconium cyclosilicate
- Volunteers
- 62 people
- Sponsor
- Guangdong Provincial People's Hospital
Secondary Hyperparathyroidism, Renal Osteodystrophy
Regulation of Bone Formation in Renal Osteodystrophy
To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure
- Trial name
- NCT00560300
- Testing
- 1 alpha D2, 1,25 dihydroxy vitamin D3, Sevelamer HCl
- Volunteers
- 61 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease, Hyperparathyroidism
Pediatric Chronic Kidney Disease Safety and Efficacy
The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease
- Trial name
- NCT01277510
- Testing
- cinacalcet capsule, Standard of Care
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 43 people
- Sponsor
- Amgen
Parathyroid Gland Disease, Secondary Hyperparathyroidism
Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT
Secondary hyperparathyroidism (SHPT) is a common serious complication in the maintenance process of hemodialysis patients, characterized by diffuse or nodular hyperplasia of parathyroid glands.
- Trial name
- NCT05540795
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Chronic Kidney Diseases, Hyperphosphatemia
Improving Phosphate Control in Children With CKD
Research goals: To explore the views and baseline knowledge of children and young people (CYP) with CKD and their caregivers to develop effective phosphate educational materials (PEM), adapted for age, and acknowledging different…
- Conditions
- Chronic Kidney Diseases, Hyperphosphatemia, Pediatric Kidney Disease, CKD-MBD
- Trial name
- IMPACT (NCT05439980)
- Testing
- Knowledge questionnaire, Focus groups
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Hyperparathyroidism, Secondary
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis
This study evaluates the metabolic and clinical results of two well recognized and accepted surgical techniques in the management of severe hyperparathyroidism in patients under regular dialysis treatment.
- Trial name
- NCT02464072
- Testing
- Subtotal Parathyroidectomy, Total Parathyroidectomy + 45 autografts, Total Parathyroidectomy + 90 autografts
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- University of Sao Paulo General Hospital
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
- Trial name
- NCT01290029
- Testing
- Cinacalcet
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, End Stage Renal Disease
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
- Trial name
- NCT00053547
- Testing
- paricalcitol injection
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Abbott